[Treatment of seronegative myasthenia garvis].
作者信息
Motomura Masakatsu
机构信息
First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University.
出版信息
Rinsho Shinkeigaku. 2007 Nov;47(11):877-9.
PMID:18210824
Abstract
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. It is classified into 1) the nicotinic acetylcholine receptor antibodies (80-85%), 2) muscle- specific tyrosine kinase antibodies (5-10%), and 3) the above-mentioned antibody absent, double seronegative MG. In this symposium, I focused the treatment of double seronegative MG.
摘要
相似文献
1
[Treatment of seronegative myasthenia garvis].
Rinsho Shinkeigaku. 2007 Nov;47(11):877-9.
2
[Pathogenic antibodies in myasthenia gravis].
Brain Nerve. 2010 Apr;62(4):411-8.
3
[Therapeutic strategy in myasthenia gravis].
Rev Neurol (Paris). 2009 Feb;165(2):149-54. doi: 10.1016/j.neurol.2009.01.005.
4
MuSK antibody-positive, seronegative myasthenia gravis in Korea.
J Clin Neurosci. 2006 Apr;13(3):353-5. doi: 10.1016/j.jocn.2005.04.028. Epub 2006 Mar 20.
5
Anti-musk antibody after thymectomy in a previously seropositive myasthenic child.
Neurology. 2007 Aug 21;69(8):803-4. doi: 10.1212/01.wnl.0000267694.45244.f4.
6
Autoimmune myasthenia gravis.
Expert Rev Neurother. 2009 Mar;9(3):351-8. doi: 10.1586/14737175.9.3.351.
7
Myasthenia and the neuromuscular junction.
Curr Opin Neurol. 2012 Oct;25(5):523-9. doi: 10.1097/WCO.0b013e3283572588.
8
A history of treatments for myasthenia gravis.
Semin Neurol. 2004 Mar;24(1):5-16. doi: 10.1055/s-2004-829584.
9
10
Myasthenia gravis and autoimmunity.
Adv Intern Med. 1980;26:489-510.
Zotero 插件